

CS/BSE/NSE/RPT/2020-21 July 3, 2020

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 530239 Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

.......

Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed disclosure of related party transactions on a consolidated basis and balances for the year ended March 31st, 2020.

We request you to take this document on your record.

Thanking you,
Yours faithfully,

For Suven Life Sciences Limited

Shrenik SoniCompany Secretary

Encl.: as above



Disclosure of related party transactions on a consolidated basis

List of related parties on consolidated basis as per Reg. 23(9)

(a) Holding Company

Jasti Property and Equity Holdings Private Limited (Holding in its capacity as sole trustee of Jasti Family Trust)

(b) Subsidiary

Suven Neurosciences Inc. (USA)

(c) Key Management personnel (KMP)

Mr. Venkateswarlu Jasti
Mrs. Sudharani Jasti
Dr. M. R. Naidu
Prof. Dr. Seyed E. Hasnain
Mr. M. Gopalakrishna
Mr. Santanu Mukherjee
Mrs. J.A.S. Padmaja

Chairman & CEO
Whole-time Director
Independent Director
Non-executive Director
Independent Director
Independent Director
Independent Director

(d) Entities with common control

Suven Pharmaceuticals Limited Suven Pharma Inc.



Transactions during the year ended 31st March, 2020 with related parties

Rupees in lakhs

Particulars	For the year ended 31st March 2020
Parent entities	
Jasti Property and Equity Holdings Private Limited (Holding in its capacity as sole trustee of Jasti Family Trust)	60.00%
Subsidiaries	
Balance outstanding	24,181.31
Key Management Personnel compensation	
Short term employee benefits	88.19
Balance outstanding	Nil
Entity with common control	
Rent Expenses	25.89
Interest Income on Loan given	1321.31
Intercorporate Loan to Suven Pharmaceuticals Ltd. i Loan Given	20874.80
ii Louii Given	12298.67
ii. Receipts during the year towards Loan Giveniii. Outstanding Loan at the year end	13325.25

Suven Life Sciences Limited